OregonTherapeutics
Pharmaceutical Manufacturing
Fr
1 employees
- Employees
- 1
OregonTherapeutics Overview
- Headquarters
- Fr
- Website
- oregon-therapeutics.com
- Industry
- Pharmaceutical Manufacturing
- Employees
- 1
- Founded
- 2014
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation Manufacturing
Keywords
About OregonTherapeutics
OregonTherapeutics is developing XCE853 : Disruptive targeted therapy “First in class” & “Best in class” in oncology. XCE853 is based on an innovative and unique mechanism of action : Inhibition of protein disulfide isomerase. OregonTherapeutics first objective is to bring XCE853 into clinical trial (phase 1) for the treatment of cancer within 2 years. Based on the scientific rationale, the priority indication is advanced pancreatic cancer. Potential additional indications are ovarian, livers, and head & neck cancers.
OregonTherapeutics Contact Details
- People in AeroLeads
- 1
OregonTherapeutics Org Chart
Sample employees and titles| Name | Title | Location | Contact |
|---|---|---|---|
| Marc-Henry Pitty | CEO Chez Oregontherapeutics |
View
|
Compare Similar Companies to OregonTherapeutics
Groupe Theos
Investment Management
SCARCELL THERAPEUTICS
Biotechnology Research
Asfalia Biologics
Biotechnology Research
MEDSENIC
Research Services
Muller Medical S.A.S
Medical Equipment Manufacturing
Neurophoenix
Biotechnology Research
Telomium
Biotechnology
YTHERA
Wellness And Fitness Services
Diotheris
Biotechnology Research
HONING BIOSCIENCES
Research